Ivacaftor hydrate

Ivacaftor hydrate (VX-770 hydrate) is an orally bioavailable CFTR potentiator, used for cystic fibrosis treatment. In Vitro Ivacaftor (10 µM) increases the PC secretion activity by 3-fold for ABCB4-G535D, 13.7-fold for ABCB4-G536R, 6.7-fold for ABCB4-S1076C, 9.4-fold for ABCB4-S1176L, and 5.7-fold for ABCB4-G1178S. Ivacaftor corrects the functional defect of ABCB4 mutants. Ivacaftor (10 μM) significantly increases CFTR activity in W1282X-expressing cells compared to R1162X CFTR cells. Ivacaftor shows no significant activity against 160 targets tested including the GABA A benzodiazepine receptor. Ivacaftor increases the chloride secretion with an EC 50 of 0.236 ± 0.200 μM, a 10-fold shift in potency compared to the F508del HBEs. In recombinant cells, VX-770 increases CFTR channel open probability (Po) in both the F508del processing mutation and the G551D gating mutation. VX-770 increases forskolin-stimulated I T in temperature-corrected F508del-FRT cells by appr 6-fold with an EC 50 of 25 nM . MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo Ivacaftor (1-200 mg/kg, p.o.) exhibits good oral bioavailability in rat. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

No numbering system information yet

No physical and chemical property information yet

No safety information yet

No production method and use information yet

No upstream information yet

No downstream information yet

No related product information yet